Product resources for your patients
Patient-friendly information about Rivfloza®, including the patient brochure and instructions for use.
Rivfloza® (nedosiran) injection 80 mg, 128 mg, or 160 mg
Rivfloza® is indicated to lower urinary oxalate levels in children 9 years of age and older and adults with primary hyperoxaluria type 1 (PH1) and relatively preserved kidney function, eg, eGFR ≥30 mL/min/1.73 m2.
Rivfloza® is indicated to lower urinary oxalate levels in children 9 years of age and older and adults with primary hyperoxaluria type 1 (PH1) and relatively preserved kidney function, eg, eGFR ≥30 mL/min/1.73 m2.
Filter
website
Rivfloza® patient website
Help your patients learn more about Rivfloza® by sharing the patient website.
PDF
Patient Brochure
Share this with your patients as a helpful reference on Rivfloza®.
PDF
Patient Brochure (Spanish)
Share this with your Spanish-speaking patients as a reference on Rivfloza®.
Administration video – vial
See how to administer Rivfloza® using the single-dose vial.
Administration video – prefilled syringe
See how to administer Rivfloza® using the prefilled syringe.
PDF
Patient Dosing and Administration Guide
Guide to help patients properly administer Rivfloza®.
PDF
NovoCare® brochure
A printable resource to help patients starting therapy.
Important Safety Information for Rivfloza®
Adverse Reactions
- Most common adverse reaction (reported in 39% of patients) are injection site reactions, which include erythema, pain, bruising, and rash.
Indications and Usage
Rivfloza® (nedosiran) injection 80 mg, 128 mg, or 160 mg is indicated to lower urinary oxalate levels in children 9 years of age and older and adults with primary hyperoxaluria type 1 (PH1) and relatively preserved kidney function, eg, eGFR ≥30 mL/min/1.73 m2.
Please click here for Rivfloza® Prescribing Information.